FTC Weighs In on Orange Book Listing of Drug-Device Patents

Start
On March 22, 2024, the Federal Trade Commission (“FTC”) filed an amicus brief in Teva Branded Pharmaceutical Products R&D, et al. v. Amneal Pharmaceuticals of New York, LLC, et al., 2:23-cv-20964, U.S. District Court for the District of New Jersey (“Teva v. Amneal”), stating that the court should grant Amneal’s motion for judgment on the pleadings to compel Teva to de-list certain patents in the U.S. Food and Drug Administration’s (“FDA”) Orange Book for Teva’s ProAir HFA product….
By: Jones Day
Previous Story

Does the EU AI Act Classify Your AI System as High Risk?

Next Story

OHRP FY 25 Budget Request Lacks Prior Plea For Funding, Staff Increases; Plans Are Modest